Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LMFAO. It's a startup. Rumor has it that Hema gets ODD then additional funding from major Pharma.
Yes, startup is accurate. Generally biotech startups place bets on a few potential drugs or therapies that yield huge payoffs...or nothing. Seven Years to get those drugs or therapies to a place where they can be monitized is reasonable.We are 5 years into that timeline with HemaXellerate. If it's too risky for most investors that's OK. I believe we're close to ODD and a SP over a dollar. That crazy to many....until it comes true.
LOL. It's a startup biotech. If it's drugs get approved and show promise we make money. If not we don't. Pretty straight forward. Very possible we see ODD very soon and a big pop. Good luck on the NYSE.
Last year mid December we received FDA approval and NIH collaboration agreement. Although Share Price was didsapointing last year I believe similar news e.g., ODD and or dCell FDA approval will have big effect moving SP to upside this year.
Orphan drug status is key to share price movement
Bid finally rising.
Tomorrow 10-Q due. Hopefully they post.
LMAO. They are waiting for FDA approval on at least two submissions, discussing, negotiating or finalizing a funding agreement with the potential partners from the 8/25 PR, preparing or just submitting an augmented FDA submission on Hema for treatments to counter the effects of chemotherapy, continuing testing small molecule compounds from the Eli Lilly resource. Seriously, stringing us along? You think their end game is to slowly bleed through small perctage dilution? Ha! No. they want what we want; to sell at the highest price their catalogue of treatments. If they need orphan drug designation or FDA approval on dcell and that takes more time then so be it.
Charts are worthless as far as this goes. It's a binary future FDA approvals and partnerships the SP launches.
Charts are worthless as far as this goes. It's a binary future FDA approvals and partnerships the SP launches.
Here we go again with the 100k prebought bids.
We will see,Squirt. I would be interested in the name of the condition where one's self worth is heightened by the financial failure of others. I believe big SP launching news soon.
LMFAO. Pessimism in the face of obvious scientific progress toward major advancements in cancer and other disease treatment seems like rearview mirror analysis. Regen is pushing treatments that may be big important players in multi billion dollar markets. This is a great OTC high risk high return play.
No, since we now have more information. I'm as optimistic as ever that a deal will be struck. In my mind it's not if but when a deal will happen. Of course I want it sooner than later but my 60 day lead time was based on the industry I'm in, and the info we had at the time. Since then we've seen two FDA submissions that prompted me to theorize that RGBP believes that their value is enhanced dramatically if they get one or both approved prior to a deal. And I believe that this is all part of their negotiation strategy with serious interested partners.
What matters is post Objective Capital partnership deal announcement. Big name partner means big PPS increase. Until then PPS floats in its current range.
LMFAO. This pig is dead. Next action a R/S.
All about what Objective Capital can make happen. See 8/25 PR.
Once Quarterly Report filed this will run, IMO. The only reason Q is late is because they were forced to change accounting firms when their's was hit with violation and they determined they could no longer use them. New firm being extra careful to issue accurate report.
I disagree. It's someone's opinion. Not objective. When someone constantly states "let's look at this objectively" they are using an 11th grade debating technique intended on presenting theory or opinion as fact.
Complete bust.
Maybe he is!!!!
Market assuming a sale. Both worth the same in that scenario.
It's down today. Not moving up at all.
It's down today. Not moving up at all.
Or an unconventional mega company that has successfully taken risks in unconventional cutting edge technologies. Just a guess.
Sorry. A total bust today.
Pipeline full.. Potential BP Partners identified. Objective Capital negotiating deal. News soon.
NITE obviously want to control this. They're on the bid and ask. What gives.
LOL. I believe you. What's the Twitter account so I can see the tweets.
Where is current chatter?. Website news is old.
Link to website?
Let's hope 275 stands. Thanks
Do you know the pref OS?
Week's progress. Lower risk, higher possible reward. It's all about BP buyout and licensing. Because of the NF study, resubmission of ODD and resubmission of DCell, the pipeline is much more secure. That means Regen is worth more to the serious BPs alluded to in the 8/25 PR. This is a fantastic binary OTC play. BP transaction means a several thousand pct increase in SP. it will happen VERY soon IMO.
I disagree. August 25 they announce that serious interest by best in class companies who are particularly interested in Hema and NF....How long from there to an inked LOI 30 to ?, 60 days? If nothing by end of October then I'll admit something's amiss. Until then I believe serious negotiations are afoot and we could hear any day. Furthermore, for all the sells by FandF there are buys at market. So 2 cent and less stock owners are rapidly being replaced by 13,14,up to 17 cent investors expecting a big payday.
Dancing with elephants. Just don't want to get squished. Only a buyout or similar transaction by investment grade BP gets this out of the hands of FandF and MMs.
Possible reasons for FDA questions
Form was improperly filled out or incomplete.
Unusual treatment/never seen before
Bait and switch concern. Is it really for aplastic anemia or more common anemic issues (eg cancer treatment)?
Possible reasons it took so long to respond
Time
Money
Limited resources
Prefs have potential dividend value. By valuing both at 15 the market believes that there will not be a dividend before a BP transaction and that they are of equal value.
Interesting how both pref and common are converging to 15
FDA submissions needed prior to finalizing a BP transaction?